The Week in Review: July 27 – August 24, 2018

Friday, August 24, 2018 News Recap: Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...

FDA OKs First-Line Tx for Unresectable Liver Cancer: First new upfront treatment option in over a decade

WASHINGTON -- The FDA on Thursday approved the kinase inhibitor lenvatinib (Lenvima) for the first-line treatment of hepatocellular carcinoma (HCC) patients with unresectable disease. Approval was based on the REFLECT study, a multicenter non-inferiority trial, which randomized 954 HCC patients 1:1 to either 8 mg or 12 mg oral lenvatinib (depending on the patient's weight) versus 400 mg sorafenib twice daily until disease progression or unacceptable toxic

The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

In HBV, high core-related antigen levels predict cirrhosis

Elevated hepatitis B virus core-related antigen levels significantly increased the risk for progression to cirrhosis among patients with chronic hepatitis B who are hepatitis B e antigen-negative and are not receiving nucleos(t)ide analogue therapy, according to recently published data. “Recently, various indices of liver fibrosis based on clinical and biological data have been reported to be useful predictors of fibrosis in liver disease,” Toshifumi Tada

“Miraculous,” new treatment for Hep C

Less than one percent of Albertans suffer from Hepatitis C, but despite that seemingly low number Dr. Mark Swain with the University of Calgary calls the infection, “prevalent.” That measurement comes in at some 40,000 people. Well, as Dr. Swain tells the Alberta Morning News, a new drug that’s just been approved seeks to help end Hep C. Epclusa is a combination of 2 drugs in one pill, with an enviable success rate. Read more...

Pre-Treatment Questions

Pre-Treatment Questions So many questions! Where to begin…?         Should I get treatment for HCV? Now? Later? Standard of Care or a Clinical Trial? How will I pay for it? Will I have to quit my job? Will my personality change?  What effect will it have on my family life? And that’s just the beginning!  It’s natural to have lots of questions, and smart to ask.  Don’t be shy.   This guide by Luci...

Current Treatments

Current HCV Treatments in BC as of March 2019 IMPORTANT: As of March 13, 2018,  anyone in B.C. living with this now-curable virus will have a choice of several treatment options – all of which are fully funded under BC PharmaCare, and all restrictions based on disease level have been removed. There are many drug combinations available for treating hepatitis C in Canada which are also covered by BC Pharmacare.  Older combinations involved the use of i


What treatment is available now for hepatitis C? It depends on where you live and your genotype (variety of hepatitis C virus you have) Note: As of March 2018, citizens and permanent residents of BC, Ontario and Quebec have unrestricted access to treatment for all genotypes, and the drugs are provided under the respective provincial PharmaCare plans which makes the drugs affordable on a sliding scale. *** Standard of Care (Description of the most common

Hep C Treatments Can Cause Adverse Effects in Older Patients

SAN FRANCISCO — Direct-acting antiviral medications can be effective in older patients with hepatitis C, but adverse reactions are common and the adjustment of other medications is often required, new research suggests."We need more data about these new treatments in the elderly," said Berta Pernas, from Corunna University Hospital in Spain."I think we can treat these patients, but caution for interactions and adverse events is required," she said here at